[go: up one dir, main page]

CR8265A - Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades mediadas por cox-2 - Google Patents

Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades mediadas por cox-2

Info

Publication number
CR8265A
CR8265A CR8265A CR8265A CR8265A CR 8265 A CR8265 A CR 8265A CR 8265 A CR8265 A CR 8265A CR 8265 A CR8265 A CR 8265A CR 8265 A CR8265 A CR 8265A
Authority
CR
Costa Rica
Prior art keywords
milk
prevention
treatment
cox
diseases mediated
Prior art date
Application number
CR8265A
Other languages
English (en)
Inventor
Hau Joerg
Mace Catherine
Bovetto Lionel
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CR8265A publication Critical patent/CR8265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)

Abstract

Se relaciona con composiciones nutricionales y farmaceuticas para el tratamiento y prevencion de enfermedades mediadas por la cicloxigenasa 2 y a un metodo para incrementar la actividad inhibidora de la cicloxigenasa 2 de un producto.
CR8265A 2003-09-12 2006-03-01 Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades mediadas por cox-2 CR8265A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03020739.3A EP1514482B2 (en) 2003-09-12 2003-09-12 Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases

Publications (1)

Publication Number Publication Date
CR8265A true CR8265A (es) 2006-07-14

Family

ID=34130196

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8265A CR8265A (es) 2003-09-12 2006-03-01 Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades mediadas por cox-2

Country Status (16)

Country Link
US (1) US8012509B2 (es)
EP (2) EP1514482B2 (es)
JP (1) JP4824560B2 (es)
CN (1) CN1849076B (es)
AR (1) AR045745A1 (es)
AT (1) ATE407574T2 (es)
AU (1) AU2004271722B2 (es)
BR (1) BRPI0413714A (es)
CA (1) CA2537544C (es)
CR (1) CR8265A (es)
DE (1) DE60323489D1 (es)
ES (1) ES2314152T3 (es)
MX (1) MXPA06002648A (es)
PT (1) PT1514482E (es)
TW (1) TW200524545A (es)
WO (1) WO2005025335A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515929A (ja) * 2005-11-14 2009-04-16 ネステク ソシエテ アノニム 糖化タンパク質を用いた経口免疫寛容促進
NL1033698C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
US20080293159A1 (en) * 2007-05-24 2008-11-27 Murray Goulburn Co-Operative Co. Ltd. Validation Process
NZ599442A (en) * 2009-10-16 2015-01-30 Dairy Australia Ltd Allergy treatment using acid treated aqueous whey protein extract
US8962042B2 (en) * 2010-09-28 2015-02-24 Lisa Geng Methods for treating neurological disorders using nutrient compositions
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
CN105613731B (zh) * 2016-03-17 2019-12-31 广西壮族自治区水牛研究所 一种发酵乳制品
WO2019229215A2 (de) * 2018-05-30 2019-12-05 DÖHLER GmbH Hochdruckverfahren, insbesondere zur haltbarmachung von lebensmitteln, pharmazeutika und kosmetika, sowie hochdruckvorrichtung
WO2020159357A1 (en) * 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748847A1 (de) * 1976-11-05 1978-05-11 Stauffer Chemical Co Verfahren zum verstaerken saurer alkoholfreier getraenke mit protein und verstaerkungsmittel auf proteinbasis
US4358464A (en) * 1977-08-02 1982-11-09 Superior Dairy, Inc. Process for converting sour whey into sweet whey and product
US4284623A (en) 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
DE3141914A1 (de) * 1981-10-22 1983-05-05 Babcock-BSH AG vormals Büttner-Schilde-Haas AG, 4150 Krefeld Verfahren zur herstellung von frischkaese
JPS6339545A (ja) * 1986-08-04 1988-02-20 Meiji Milk Prod Co Ltd 牛乳ホエ−中のβ−ラクトグロブリンの除去方法
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
JP2622686B2 (ja) * 1987-05-15 1997-06-18 雪印乳業株式会社 ｋ−カゼイングリコマクロペプチドの製造法
US5888552A (en) 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DE4413839C1 (de) 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
DE19649891C2 (de) * 1996-12-02 1998-12-10 Mk Produktkontor Gmbh Verwendung von antioxidativen Zusammensetzungen mit Süßmolkekonzentrat
DE19726868A1 (de) * 1997-06-24 1999-01-07 Mk Produktkontor Gmbh Antioxidative Zusammensetzungen mit Süßmolkekonzentrat
MXPA00012399A (es) * 1998-06-10 2003-07-14 Albert B Crum Complememnto nutricional profilactico y terapeutico para la creacion y mantenimiento de microflora intestinal protectora de la salud y mejoramiento del sistema inmunologico.
US6558716B1 (en) * 1999-01-14 2003-05-06 Kraft Foods Holdings, Inc. Process for incorporating whey protein into cheese
DE19918219C1 (de) * 1999-04-22 2001-01-18 Dornier Gmbh Lebensdauer-Indikator für hochbeanspruchte Leichtbau-Strukturen
DE19918210A1 (de) 1999-04-22 2000-11-02 Biomun Gmbh Verfahren zur Herstellung eines Milchpräparates mit verzögerter Inhaltsstoff-Freisetzung und seine Verwendung
RU2275041C2 (ru) 1999-04-29 2006-04-27 Сосьете Де Продюи Нестле С.А. Состав молочной смеси, способ его получения и молочная смесь, содержащая его (варианты)
US6469063B1 (en) * 1999-11-18 2002-10-22 City Of Hope Inhibition of inflammation via inhibition of COX-2 gene transcription
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
FR2808444B1 (fr) 2000-05-05 2004-03-26 Francois Ballestra Utilisation d'une fraction du lait d'equide pour la fabrication d'une composition possedant une activite d'inhibition de la production de l'interleukine-1 et composition ainsi obtenue
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
CN1529618A (zh) * 2000-12-22 2004-09-15 �Ʒ� 耐受性诱导
US20020169195A1 (en) * 2001-01-26 2002-11-14 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
US6589574B2 (en) * 2001-03-19 2003-07-08 Council Of Scientific & Industrial Research Process for preparation of protein-hydrolysate from milk protein
US20030026845A1 (en) * 2001-06-18 2003-02-06 Etzel Lisa R. Process for preparing protein isolate from milk, whey, colostrum, and the like
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
DE10208034A1 (de) 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt

Also Published As

Publication number Publication date
ATE407574T2 (de) 2008-09-15
US8012509B2 (en) 2011-09-06
JP4824560B2 (ja) 2011-11-30
EP1955602B1 (en) 2018-04-04
BRPI0413714A (pt) 2006-10-17
EP1514482B2 (en) 2016-06-22
JP2007505078A (ja) 2007-03-08
AU2004271722A1 (en) 2005-03-24
AR045745A1 (es) 2005-11-09
ES2314152T3 (es) 2009-03-16
MXPA06002648A (es) 2006-06-05
DE60323489D1 (de) 2008-10-23
US20070110818A1 (en) 2007-05-17
PT1514482E (pt) 2008-11-19
WO2005025335A1 (en) 2005-03-24
CA2537544C (en) 2012-12-11
AU2004271722B2 (en) 2010-12-16
CN1849076B (zh) 2010-06-09
CN1849076A (zh) 2006-10-18
TW200524545A (en) 2005-08-01
EP1955602A1 (en) 2008-08-13
EP1514482A1 (en) 2005-03-16
CA2537544A1 (en) 2005-03-24
EP1514482B1 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
FR3027228B1 (fr) Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
WO2005027977A3 (en) Diclofenac compositions for the treatment of skin disorders
EP4008718C0 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE
CR8265A (es) Fracciones de leche y preparaciones de leche para el tratamiento y/o prevencion de enfermedades mediadas por cox-2
ITRM20020014A1 (it) Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
TW200612903A (en) Use of trisubstituted benzopyranones
AU2003271807A1 (en) Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same
ATE454889T1 (de) Arzneimittel zur behandlung von sarkoglykanopathien
WO2002015721A3 (de) Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
FR2857026B1 (fr) Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
UA94434C2 (ru) Экстракт коры дерева рода corynanthe и его применение, лекарственное средство, пищевой продукт с лекарственными или профилактическими свойствами и фармацевтический препарат, который его содержит
DK1497250T3 (da) Hyperforinderivater, anvendelse heraf og sammensætninger indeholdende disse
ATE417035T1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen